Satisfaction of Treatment Among Elderly Patients With Insulin Therapy
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Several studies have shown that high blood sugar (glucose) levels are associated with
diseases caused by diabetes. Controlling the glucose may prevent these complications. As
people age, their bodies become unable to make enough insulin to control the blood sugars.
Pills used to treat diabetes may help for a while, but many times this does not last. When
the blood sugar is too high, insulin is frequently recommended and used to treat diabetes.
Insulin is often started by adding a long-acting insulin to the medicines a patient already
takes. In this study, glargine insulin will be taken together with the diabetes pills
currently being used. Glargine is a long-acting insulin which is given under the skin once a
day. Glargine is approved for use in the treatment of patients with diabetes by the FDA (Food
and Drug Administration).
Currently, insulin delivery is only available as a shot. The purpose of this study is to
compare how satisfied patients are when using two different types of insulin shots.
Specifically, this study aims to determine if people over 65 years old are more satisfied
taking insulin shots by pens or syringes. Everyone who joins in this study will have a chance
to use the insulin syringes and the insulin pens.
The ability of patients to give themselves shots can affect how well the sugar is controlled.
As people age, medical and other problems may develop that affect their ability to do certain
things. Another aim of this study is to determine if the ability to use an insulin pen and
insulin syringe is affected by age or some other problem.
During this study, participants will be treated with insulin given by a syringe for 12 weeks
and by a pen for 12 weeks. Questionnaires will be given to determine satisfaction with
treatment throughout the study. The investigators hypothesize that among elderly patients
with type 2 diabetes mellitus failing oral agent therapy, treatment with basal insulin via a
pen device results in higher treatment satisfaction scores and more accurate dosing than
treatment with basal insulin via conventional vial and syringe methods.
A total of 56 subjects with type 2 diabetes will be recruited into this study. The site for
the study is Grady Memorial Hospital clinics in Atlanta, Georgia.